Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free BMY Stock Alerts

Bristol Myers Squibb (BMY) Competitors

Bristol Myers Squibb logo
$57.17 +0.26 (+0.46%)
Closing price 05/29/2026 03:59 PM Eastern
Extended Trading
$57.10 -0.08 (-0.13%)
As of 05/29/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

Should you buy Bristol Myers Squibb stock or one of its competitors? MarketBeat compares Bristol Myers Squibb with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bristol Myers Squibb include Amgen (AMGN), Exelixis (EXEL), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and AbbVie (ABBV). These companies are all part of the "medical" sector.

How does Bristol Myers Squibb compare to Amgen?

Bristol Myers Squibb (NYSE:BMY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Bristol Myers Squibb had 9 more articles in the media than Amgen. MarketBeat recorded 37 mentions for Bristol Myers Squibb and 28 mentions for Amgen. Amgen's average media sentiment score of 1.27 beat Bristol Myers Squibb's score of 1.07 indicating that Amgen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bristol Myers Squibb
23 Very Positive mention(s)
7 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
3 Very Negative mention(s)
Positive
Amgen
22 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Amgen has lower revenue, but higher earnings than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol Myers Squibb$48.19B2.42$7.05B$3.5616.06
Amgen$36.75B4.95$7.71B$14.3723.44

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.4%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.0%. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Amgen pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has raised its dividend for 17 consecutive years and Amgen has raised its dividend for 14 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Amgen has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amgen has a net margin of 20.96% compared to Bristol Myers Squibb's net margin of 15.01%. Amgen's return on equity of 137.41% beat Bristol Myers Squibb's return on equity.

Company Net Margins Return on Equity Return on Assets
Bristol Myers Squibb15.01% 64.87% 13.16%
Amgen 20.96%137.41%13.28%

Bristol Myers Squibb presently has a consensus price target of $61.31, suggesting a potential upside of 7.24%. Amgen has a consensus price target of $355.19, suggesting a potential upside of 5.46%. Given Bristol Myers Squibb's higher probable upside, research analysts clearly believe Bristol Myers Squibb is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bristol Myers Squibb
1 Sell rating(s)
10 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.37
Amgen
2 Sell rating(s)
14 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.48

Summary

Amgen beats Bristol Myers Squibb on 15 of the 20 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Exelixis?

Bristol Myers Squibb (NYSE:BMY) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, Exelixis had 1 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 38 mentions for Exelixis and 37 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 1.07 beat Exelixis' score of 0.75 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bristol Myers Squibb
23 Very Positive mention(s)
7 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
3 Very Negative mention(s)
Positive
Exelixis
13 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Bristol Myers Squibb has higher revenue and earnings than Exelixis. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol Myers Squibb$48.19B2.42$7.05B$3.5616.06
Exelixis$2.32B5.47$782.57M$3.0116.77

Bristol Myers Squibb currently has a consensus target price of $61.31, suggesting a potential upside of 7.24%. Exelixis has a consensus target price of $47.35, suggesting a potential downside of 6.19%. Given Bristol Myers Squibb's higher possible upside, research analysts clearly believe Bristol Myers Squibb is more favorable than Exelixis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bristol Myers Squibb
1 Sell rating(s)
10 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.37
Exelixis
2 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.39

Bristol Myers Squibb has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Exelixis has a net margin of 35.08% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Exelixis' return on equity.

Company Net Margins Return on Equity Return on Assets
Bristol Myers Squibb15.01% 64.87% 13.16%
Exelixis 35.08%39.89%30.23%

Summary

Exelixis beats Bristol Myers Squibb on 11 of the 17 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.4%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.4%. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 10 consecutive years and Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Gilead Sciences presently has a consensus target price of $156.93, suggesting a potential upside of 16.73%. Bristol Myers Squibb has a consensus target price of $61.31, suggesting a potential upside of 7.24%. Given Gilead Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Gilead Sciences is more favorable than Bristol Myers Squibb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilead Sciences
0 Sell rating(s)
4 Hold rating(s)
25 Buy rating(s)
0 Strong Buy rating(s)
2.86
Bristol Myers Squibb
1 Sell rating(s)
10 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.37

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Gilead Sciences has a net margin of 30.99% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Gilead Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Gilead Sciences30.99% 48.19% 18.28%
Bristol Myers Squibb 15.01%64.87%13.16%

In the previous week, Gilead Sciences and Gilead Sciences both had 37 articles in the media. Gilead Sciences' average media sentiment score of 1.47 beat Bristol Myers Squibb's score of 1.07 indicating that Gilead Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gilead Sciences
32 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Bristol Myers Squibb
23 Very Positive mention(s)
7 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
3 Very Negative mention(s)
Positive

Gilead Sciences has higher earnings, but lower revenue than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$29.44B5.67$8.51B$7.3418.31
Bristol Myers Squibb$48.19B2.42$7.05B$3.5616.06

Summary

Gilead Sciences beats Bristol Myers Squibb on 14 of the 18 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Vertex Pharmaceuticals currently has a consensus price target of $555.91, suggesting a potential upside of 24.22%. Bristol Myers Squibb has a consensus price target of $61.31, suggesting a potential upside of 7.24%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Vertex Pharmaceuticals is more favorable than Bristol Myers Squibb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vertex Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
22 Buy rating(s)
0 Strong Buy rating(s)
2.88
Bristol Myers Squibb
1 Sell rating(s)
10 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.37

In the previous week, Bristol Myers Squibb had 7 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 37 mentions for Bristol Myers Squibb and 30 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.21 beat Bristol Myers Squibb's score of 1.07 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vertex Pharmaceuticals
21 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Bristol Myers Squibb
23 Very Positive mention(s)
7 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
3 Very Negative mention(s)
Positive

Vertex Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Bristol Myers Squibb has higher revenue and earnings than Vertex Pharmaceuticals. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$12.00B9.46$3.95B$16.8626.54
Bristol Myers Squibb$48.19B2.42$7.05B$3.5616.06

Vertex Pharmaceuticals has a net margin of 35.51% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Vertex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Vertex Pharmaceuticals35.51% 23.86% 17.13%
Bristol Myers Squibb 15.01%64.87%13.16%

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Bristol Myers Squibb on 12 of the 16 factors compared between the two stocks.

How does Bristol Myers Squibb compare to AbbVie?

AbbVie (NYSE:ABBV) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

AbbVie has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

In the previous week, AbbVie had 18 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 55 mentions for AbbVie and 37 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 1.07 beat AbbVie's score of 1.06 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AbbVie
37 Very Positive mention(s)
7 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive
Bristol Myers Squibb
23 Very Positive mention(s)
7 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
3 Very Negative mention(s)
Positive

70.2% of AbbVie shares are held by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bristol Myers Squibb has a net margin of 15.01% compared to AbbVie's net margin of 5.79%. Bristol Myers Squibb's return on equity of 64.87% beat AbbVie's return on equity.

Company Net Margins Return on Equity Return on Assets
AbbVie5.79% -576.45% 13.39%
Bristol Myers Squibb 15.01%64.87%13.16%

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.2%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.4%. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. AbbVie has raised its dividend for 53 consecutive years and Bristol Myers Squibb has raised its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Bristol Myers Squibb has lower revenue, but higher earnings than AbbVie. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$61.16B6.29$4.23B$2.03107.30
Bristol Myers Squibb$48.19B2.42$7.05B$3.5616.06

AbbVie currently has a consensus price target of $253.43, indicating a potential upside of 16.34%. Bristol Myers Squibb has a consensus price target of $61.31, indicating a potential upside of 7.24%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts clearly believe AbbVie is more favorable than Bristol Myers Squibb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AbbVie
0 Sell rating(s)
6 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.88
Bristol Myers Squibb
1 Sell rating(s)
10 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.37

Summary

AbbVie beats Bristol Myers Squibb on 12 of the 20 factors compared between the two stocks.

Get Bristol Myers Squibb News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMY vs. The Competition

Export
MetricBristol Myers SquibbMED IndustryMedical SectorNYSE Exchange
Market Cap$116.77B$3.41B$6.58B$23.19B
Dividend Yield4.41%2.29%2.68%4.09%
P/E Ratio16.0610.3918.2227.79
Price / Sales2.42334.85561.7724.75
Price / Cash7.0354.1927.4419.43
Price / Book6.296.9310.044.70
Net Income$7.05B$24.20M$3.56B$1.07B
7 Day Performance-3.92%4.11%2.85%1.14%
1 Month Performance-5.89%6.66%4.59%1.26%
1 Year Performance18.47%66.00%37.62%28.06%

Bristol Myers Squibb Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMY
Bristol Myers Squibb
4.6327 of 5 stars		$57.17
+0.5%		$61.31
+7.2%		+18.5%$116.77B$48.19B16.0632,500
AMGN
Amgen
4.2154 of 5 stars		$337.42
+1.8%		$355.19
+5.3%		+17.3%$178.94B$36.75B23.4831,500
EXEL
Exelixis
2.6903 of 5 stars		$49.65
-0.5%		$47.35
-4.6%		+17.9%$12.54B$2.32B16.501,077
GILD
Gilead Sciences
4.761 of 5 stars		$130.50
-0.1%		$156.93
+20.2%		+21.8%$162.26B$29.44B17.7817,000
VRTX
Vertex Pharmaceuticals
4.5414 of 5 stars		$433.54
+0.7%		$555.17
+28.1%		+1.0%$109.25B$12.00B25.716,400

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:BMY) was last updated on 5/31/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel